Compare IDYA & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | MLCO |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2019 | 2006 |
| Metric | IDYA | MLCO |
|---|---|---|
| Price | $31.70 | $6.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $52.86 | $10.10 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $218,710,000.00 | N/A |
| Revenue This Year | N/A | $5.42 |
| Revenue Next Year | $201.05 | $4.37 |
| P/E Ratio | ★ N/A | $12.16 |
| Revenue Growth | ★ 3024.43 | N/A |
| 52 Week Low | $16.82 | $4.88 |
| 52 Week High | $39.28 | $10.15 |
| Indicator | IDYA | MLCO |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 60.00 |
| Support Level | $29.51 | $5.92 |
| Resistance Level | $34.76 | $6.25 |
| Average True Range (ATR) | 2.02 | 0.17 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 19.44 | 93.04 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.